Asahi Kasei Elevates Two Medical Device Subsidiaries
This article was originally published in PharmAsia News
Executive Summary
Asahi Kasei Group announced July 25 it will take two subsidiaries, Tokyo-based Asahi Kasei Medical and Asahi Kasei Kuraray Medical, which are currently under Asahi Kasei Pharma, into its own direct subsidiaries starting in October. The two companies manufacture and market artificial dialysis and blood filtration products. Asahi Kasei's move aims to strengthen its medical device business. (Click here for more - Japanese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.